[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Gupta et al., 2020 - Google Patents

Infantile fibrosarcoma–like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib

Gupta et al., 2020

View PDF @Free from Publisher
Document ID
1033998410147082683
Author
Gupta A
Belsky J
Schieffer K
Leraas K
Varga E
McGrath S
Koo S
Magrini V
Wilson R
White P
Mardis E
Jatana K
Cottrell C
Setty B
Publication year
Publication venue
Molecular Case Studies

External Links

Snippet

Infantile fibrosarcoma (IFS) is nearly universally driven by gene fusions involving the NTRK family. ETV6-NTRK3 fusions account for∼ 85% of alterations; the remainder are attributed to NTRK-variant fusions. Rarely, other genomic aberrations have been described in …
Continue reading at molecularcasestudies.cshlp.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Similar Documents

Publication Publication Date Title
Pfister et al. A summary of the inaugural WHO classification of pediatric tumors: transitioning from the optical into the molecular era
JP7030860B2 (en) Mutation detection and chromosomal segment ploidy
Pitt et al. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features
Cancer Genome Atlas Research Network Integrated genomic characterization of oesophageal carcinoma
Li et al. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy
Tian et al. Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer
Gupta et al. Infantile fibrosarcoma–like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib
Chiosea et al. Molecular characterization of apocrine salivary duct carcinoma
Ma et al. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer
Jiang et al. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment
Lenkiewicz et al. Genomic and epigenomic landscaping defines new therapeutic targets for adenosquamous carcinoma of the pancreas
AU2019251504A1 (en) Methods for cancer detection and monitoring by means of personalized detection of circulating tumor DNA
Ansari-Pour et al. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes
Park et al. Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling
Jeon et al. Clinical implementation of precision medicine in gastric cancer
Qvick et al. Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
Hansen et al. Clinical application of high-throughput genomic technologies for treatment selection in breast cancer
Murria et al. Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer
Park et al. Molecular Characterization and Putative pathogenic pathways of tuberous sclerosis complex–associated renal cell carcinoma
Penter et al. Integrative genotyping of cancer and immune phenotypes by long-read sequencing
Shi et al. Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment
Rezayee et al. Feasibility to use whole-genome sequencing as a sole diagnostic method to detect genomic aberrations in pediatric B-cell acute lymphoblastic leukemia
Yang et al. Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas
Lyu et al. A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia
Cancer Genome Atlas Research Network Analysis Working Group: Asan University Kim Jihun 1 et al. Integrated genomic characterization of oesophageal carcinoma